FiercePharma8d
Novo Nordisk wins hard-fought FDA approval for once-daily hemophilia med Alhemo
Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...
Managed Healthcare Executive8d
Alhemo Once-Daily Treatment for Hemophilia A, B with Inhibitors FDA Approved
The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...
Zacks.com on MSN7d
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer ... recommending the approval of Alhemo (concizumab) for ...
BioWorld8d
Novo’s injectable hemophilia treatment approved by FDA
With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce ...
The Pharma Letter9d
FDA approves Novo Nordisk’s Alhemo
Denmark’s Novo Nordisk said late Friday that the US Food and Drug Administration (FDA) has approved Alhemo (concizumab-mtci) ...
Seeking Alpha10d
Novo Nordisk bleeding prevention injection for hemophilia granted FDA nod
Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration (FDA) has approved its Alhemo (concizumab-mtci) bleeding prevention injection for patients with rare clotting disorders ...
The American Journal of Managed Care8d
First Subcutaneous Prophylaxis for Hemophilia A and B With Inhibitors Approved by FDA
The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with ...
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
Nasdaq7d
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
recommending the approval of Alhemo (concizumab) for haemophilia A or B with inhibitors. A final decision is expected soon. Alhemo is not approved in the United States. Novo Nordisk is trading ...